About the Event
Nearly once every hour in the U.S., an infant is born with brain damage due to Hypoxic Ischemic Encephalopathy (HIE). HIE is responsible for 23% of infant deaths world-wide and results from lack of oxygen and blood rushing back to the brain causing severe inflammation.
ReAlta Life Sciences has developed RLS-0071, a treatment that dramatically improves outcomes for babies effected by HIE. In vitro, ex vivo, and animal tests show RLS-0071 decreases the area of brain tissue injury by 50% and dramatically improves neuro-cognitive outcomes.
The results are so promising the company has received Pediatric Orphan Drug designation from the FDA.
Join our webinar with ReAlta CEO, Ulrich Thienel, MD, to hear why babies once destined to be wheelchair bound for life will be able to walk and infants who may have died from HIE can not only survive, but also thrive.